Skip to content

Azithromycin Reduction to Reach Elimination of Trachoma B

Azithromycin Reduction to Reach Elimination of Trachoma B

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06289647
Acronym
ARRET
Enrollment
0
Registered
2024-03-04
Start date
2024-10-01
Completion date
2029-08-31
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trachoma

Brief summary

The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maniema, DRC. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.

Interventions

DRUGAzithromycin

In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.

Sponsors

University of California, San Francisco
Lead SponsorOTHER
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
CollaboratorOTHER
National Eye Institute (NEI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Double (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Months to 9 Years
Healthy volunteers
Yes

Inclusion criteria

* Provision of appropriate informed consent * Stated willingness to comply with all study procedures * Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Exclusion criteria

* Does not consent to participation * Unwilling to comply with all study procedures * Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Design outcomes

Primary

MeasureTime frameDescription
Ocular chlamydia measured in a population-based sample of 0-9 year-old children36 monthsAssessed by PCR.

Secondary

MeasureTime frameDescription
Infectious load of chlamydia among 0-9-year-old children infected with ocular chlamydia36 monthsAssessed by PCR.
Conjunctival inflammation36 monthsAssessed from conjunctival photography. Clinical photographs of the conjunctiva will be assessed by masked graders according to the grading scale described by the WHO Simplified Grading System. The system includes five signs, each of which can be present or absent: Trachomatous inflammation - follicular Trachomatous inflammation-intense Trachomatous scarring Trachomatous trichiasis Corneal opacity

Countries

Democratic Republic of the Congo

Contacts

PRINCIPAL_INVESTIGATORCatherine Oldenburg, ScD, MPH

University of California, San Francisco

PRINCIPAL_INVESTIGATORThomas Lietman, MD

University of California, San Francisco

STUDY_DIRECTORElodie Lebas, RN

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026